Roth Affirms Ligand (LGND) at 'Buy' Following Amgen (AMGN), Spectrum (SPPI) Updates
Tweet Send to a Friend
Roth Capital affirmed Ligand Pnarma (Nasdaq: LGND) at Buy with a price target of $116 after partner Amgen (Nasdaq: AMGN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
